TRCT
MIRM icon

Tower Research Capital (TRC)’s Mirum Pharmaceuticals MIRM Stock Holding History

Tower Research Capital (TRC)’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$521K Buy
5,640
+3,481
+161% +$327K 0.01% 883
2025
Q4 		$171K Buy
2,159
+725
+51% +$52K ﹤0.01% 1557
2025
Q3 		$105K Sell
1,434
-3,354
-70% -$213K ﹤0.01% 1946
2025
Q2 		$244K Buy
4,788
+3,810
+390% +$170K 0.01% 1595
2025
Q1 		$44.1K Sell
978
-4,134
-81% -$195K ﹤0.01% 2314
2024
Q4 		$211K Buy
5,112
+3,694
+261% +$154K ﹤0.01% 1682
2024
Q3 		$55.3K Sell
1,418
-5,779
-80% -$231K ﹤0.01% 2668
2024
Q2 		$246K Buy
7,197
+3,844
+115% +$101K ﹤0.01% 1914
2024
Q1 		$84.2K Sell
3,353
-882
-21% -$24.2K ﹤0.01% 1924
2023
Q4 		$125K Buy
4,235
+2,642
+166% +$80K ﹤0.01% 2466
2023
Q3 		$50.3K Sell
1,593
-253
-14% -$6.93K ﹤0.01% 2543
2023
Q2 		$47.8K Buy
1,846
+1,202
+187% +$32K ﹤0.01% 2620
2023
Q1 		$15K Sell
644
-1,685
-72% -$38.4K ﹤0.01% 3796
2022
Q4 		$45K Buy
2,329
+119
+5% +$2.35K ﹤0.01% 2433
2022
Q3 		$46K Sell
2,210
-593
-21% -$14.3K ﹤0.01% 3237
2022
Q2 		$55K Sell
2,803
-2,876
-51% -$67.8K ﹤0.01% 2798
2022
Q1 		$125K Buy
5,679
+1,611
+40% +$32.9K ﹤0.01% 2048
2021
Q4 		$65K Buy
4,068
+3,486
+599% +$54.2K ﹤0.01% 2559
2021
Q3 		$12K Sell
582
-63
-10% -$1.02K ﹤0.01% 4158
2021
Q2 		$11K Buy
645
+8
+1% +$143 ﹤0.01% 4329
2021
Q1 		$13K Sell
637
-4,920
-89% -$94.2K ﹤0.01% 4207
2020
Q4 		$97K Sell
5,557
-979
-15% -$19.2K ﹤0.01% 2383
2020
Q3 		$126K Buy
6,536
+5,376
+463% +$115K ﹤0.01% 2954
2020
Q2 		$23K Buy
+1,160
New +$19.4K ﹤0.01% 3605
2019
Q4 		– Sell
-886
Closed -$9K – 4057
2019
Q3 		$9K Buy
+886
New +$10.9K ﹤0.01% 3001

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Tower Research Capital (TRC)'s MIRM Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Mirum Pharmaceuticals (MIRM) stake by 161% in Q1 2026, buying an estimated $327K and bringing the position to 5,640 shares worth $521K. The position accounts for 0.01% of the portfolio, ranked #883.

Tower Research Capital (TRC) first reported a position in MIRM in Q3 2019 and has held it in 25 quarters since. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • Tower Research Capital (TRC) held 5,640 shares of Mirum Pharmaceuticals worth $521K as of Q1 2026.
  • Tower Research Capital (TRC) bought 3,481 Mirum Pharmaceuticals shares in Q1 2026, an estimated $327K.
  • Mirum Pharmaceuticals made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #883 holding.
  • Tower Research Capital (TRC) first reported a position in Mirum Pharmaceuticals in Q3 2019 and has held it in 25 quarters since.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.